An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alberta
-
Calgary, Alberta, Kanada
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone
- Alabama
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone
- Arizona
-
-
California
-
Los Angeles, California, Stany Zjednoczone
- California
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone
- Colorado
-
-
Florida
-
Bradenton, Florida, Stany Zjednoczone
- Florida
-
Miami, Florida, Stany Zjednoczone
- Florida
-
-
Illinois
-
Evanston, Illinois, Stany Zjednoczone
- Illinios
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone
- Indiana
-
-
Massachusetts
-
Burlington, Massachusetts, Stany Zjednoczone
- Massachusetts
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone
- Michigan
-
Detroit, Michigan, Stany Zjednoczone
- Michigan
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone
- Missouri
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone
- Nebraska
-
-
New York
-
New York, New York, Stany Zjednoczone
- New York
-
Rochester, New York, Stany Zjednoczone
- New York
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone
- North Carolina
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone
- Ohio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone
- Pennsylvania
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone
- Texas
-
Houston, Texas, Stany Zjednoczone
- Texas
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male and female participants between the ages of 18 and 65 years
- History of orthotopic liver transplantation less than 10 years before the Screening visit but no sooner than 6 months before Day 1
- Taking a stable immunosuppressant regimen based on either tacrolimus or cyclosporine without substantial dose changes over the past 3 months
- Naive to pegylated interferon/ribavirin treatment or experienced with pegylated interferon/ribavirin prior to transplantation with relapse, partial, or null response
Exclusion Criteria:
- Documented cirrhosis after liver transplantation
- Ascites or hepatic encephalopathy within 6 months before Screening
- Retransplantation for recurrent hepatitis C
- Treatment for hepatitis C post liver transplantation
- History within the past 3 months of: rejection within 3 months or greater than (>) 1 rejection within 12 months
- Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (<5 milligram per day) is permitted
- History within 3 months of any bacterial infection requiring >1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with end-organ involvement, fungal disease (except cutaneous and mild oral thrush)
- History of post transplant lymphoproliferative disease
- Acceptable laboratory values at Screening as specified in the protocol
- Positive for human immunodeficiency virus 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or Hepatitis B deoxyribonucleic acid (DNA) or Hepatitis B surface antigen
- History of hepatocellular carcinoma with high risk of recurrence
- Any other cause of liver disease deemed clinically significant by the investigator in addition to hepatitis C
- Autoimmune-mediated disease
- History of acute pancreatitis within 5 years before the Screening visit
- Prior treatment with an hepatitis C virus (HCV) protease inhibitor
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: T/PR + Immunosuppressant Regimen (Tacrolimus)
Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tablet
Inne nazwy:
Tablet
Inne nazwy:
Wstrzyknięcie podskórne
Inne nazwy:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
|
Eksperymentalny: T/PR + Immunosuppressant Regimen (Cyclosporine)
Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tablet
Inne nazwy:
Tablet
Inne nazwy:
Wstrzyknięcie podskórne
Inne nazwy:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
Ramy czasowe: 12 weeks after last planned dose of study drug (up to Week 60)
|
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (<lower limit of quantification) at 12 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 international units per milliliter (IU/mL).
|
12 weeks after last planned dose of study drug (up to Week 60)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
Ramy czasowe: 24 weeks after last planned dose of study drug (up to Week 72)
|
SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL.
|
24 weeks after last planned dose of study drug (up to Week 72)
|
|
Percentage of Participants With Rapid Viral Response (RVR)
Ramy czasowe: Week 4
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.
|
Week 4
|
|
Percentage of Participants With Extended Rapid Viral Response (eRVR)
Ramy czasowe: Week 4 and Week 12
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.
|
Week 4 and Week 12
|
|
Percentage of Participants With On-Treatment Virologic Failure
Ramy czasowe: Baseline up to Week 48
|
On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks).
Data for this outcome was not planned to be reported by prior response.
|
Baseline up to Week 48
|
|
Percentage of Participants With Viral Relapse
Ramy czasowe: 48 weeks
|
48 weeks
|
|
|
Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)
Ramy czasowe: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications
Ramy czasowe: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Biopsy Confirmed and Treated Rejection
Ramy czasowe: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage
Ramy czasowe: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Ramy czasowe: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Ramy czasowe: Baseline up to Week 52
|
Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not.
An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug.
SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
"Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.
|
Baseline up to Week 52
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Ramy czasowe |
|---|---|
|
Percentage of Participants With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
Ramy czasowe: 4 weeks after last planned dose of study drug (up to Week 52)
|
4 weeks after last planned dose of study drug (up to Week 52)
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Zakażenia wirusem RNA
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby wątroby
- Infekcje Flaviviridae
- Zapalenie wątroby, wirusowe, ludzkie
- Zapalenie wątroby
- Wirusowe zapalenie wątroby typu C
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Środki przeciwwirusowe
- Antymetabolity
- Środki przeciwnowotworowe
- Czynniki immunologiczne
- Interferony
- Interferon-alfa
- Rybawiryna
- Peginterferon alfa-2a
- Interferon alfa-2
- Środki immunosupresyjne
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- VX11-950-117
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .